close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
AstraZeneca said on Friday its and Daiichi Sankyo’s cancer drug Enhertu was recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).
The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.
EU INITIATES ASSESSMENT OF HUMAN AND LABOR RIGHTS IN BURMA
AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. (AstraZeneca/Handout via REUTERS/File photo)
CLICK HERE TO GET THE FOX NEWS APP
The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.
Recommendations made by the human medicines committee will have to be formally approved by the European Commission.
Columbia University recently confirmed a major cyberattack that compromised personal, financial and health-related information tied…
Rental car drivers are now turning to artificial intelligence to protect themselves from surprise damage…
IN TODAY’S NEWSLETTER: - Google CEO, major tech leaders join first lady Melania Trump at…
Thousands of people have had their sensitive personal information exposed in a data breach at…
Technology keeps changing the way we work, connect and even form relationships. Now it is…
Over a year ago, National Public Data (NPD) made headlines for one of the largest…